Advances in the Management of Dementia-Related Psychosis in Long-Term Care (CME/CE Webcast)
The prevalence of dementias is rising rapidly in the United States. The incidence of associated neuropsychiatric issues, including psychosis, will increase in tandem. Dementia-related psychosis places a considerable burden on affected individuals and their caregivers alike. In this educational activity, new and emerging, evidence-based strategies for evaluation, diagnosis, and treatment of dementia-related psychosis are presented, and educational tools clinicians can use in their facilities are also provided. The desired results of this activity are for clinicians working in long-term care facilities to recognize psychosis in affected persons with dementia and create person-centered, safe, and effective management plans.
This continuing medical education activity is provided by MedEdicus LLC.
This continuing medical education activity is supported through an educational grant from ACADIA Pharmaceuticals Inc.
Target Audience
This educational activity is intended for nurses, physicians, and caregivers in long-term care settings.
Learning Objectives
After completing this activity, participants will be better able to:
- Identify the signs and symptoms of dementia-related psychosis in a variety of care settings
- Apply current diagnostic criteria for dementia-related psychosis to patient scenarios specific to long-term care
- Discuss safety and efficacy data for off-label and investigational treatments for dementia-related psychosis
- Develop evidence-based, safe treatment plans for individuals with dementia-related psychosis in the long-term care setting
FACULTY
Fay Hardison Bembry, RN, MSN, FNP-BC, PMHNP-BC Psychiatric Mental Health Nurse Practitioner Team Health Behavioral Health Services Johnson City, Tennessee |
George T. Grossberg, MD Samuel W. Fordyce Professor Director, Geriatric Psychiatry Department of Psychiatry and Behavioral Neuroscience Saint Louis University School of Medicine St Louis, Missouri |
Disclosure Policy
MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity.
Faculty
Fay Hardison Bembry, RN, MSN, is on the speakers bureau for ACADIA Pharmaceuticals, Inc; Avanir Pharmaceuticals, Inc; and Myriad Neuroscience.
George T. Grossberg, MD, is a consultant for ACADIA Pharmaceuticals, Inc, Avanir Pharmaceuticals, Inc, Axsome Therapeutics, Inc, Biogen Idec, BioXcel Therapeutics, Karuna Therapeutics, and Otsuka America Pharmaceutical, Inc; and is on the speakers bureau for ACADIA Pharmaceuticals, Inc.
Peer Reviewer
This activity was peer reviewed. The peer reviewer has no relevant financial relationships.
Planners and Managers
MedEdicus planners and managers have no relevant commercial relationships to disclose.
For Physicians:
Accreditation Statement
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For Nurses:
Interprofessional Joint Accreditation Statement
In support of improving patient care, Amedco is jointly accredited by the ACCME, the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Nursing Credit
Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hour.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from ACADIA Pharmaceuticals Inc.
Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Amedco, MedEdicus LLC, or ACADIA Pharmaceuticals Inc.
This CE/CME activity is copyrighted to MedEdicus LLC ©2021. All rights reserved. 237
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation
Clicking Register indicates that you have reviewed the CME information for this activity.
Learning Method and Medium
This educational activity consists of a webcast and six (6) study questions. The participant should, in order, read the learning objectives, complete the pretest, view the webcast, answer all questions in the posttest, and complete the evaluation. To receive credit for this activity, please complete the posttest and evaluation. This educational activity should take a maximum of 1.0 hour to complete.